Skip to content
lifestyle.socialsinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nanobiotix S.A.
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
May 30, 2026
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
May 30, 2026
Nanobiotix Announces Launch of Global Follow-On Offering
May 30, 2026
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
May 29, 2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
May 27, 2026
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
May 25, 2026
Voting Rights and Shares Capital of the Company
May 24, 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
May 22, 2026
NANOBIOTIX Statement Regarding Recent Media Speculation
May 22, 2026
Voting Rights and Shares Capital of the Company
May 19, 2026
←
Previous Page
1
2
3
Next Page
→